Chemokine Therapeutics has started patient dosing in a Phase Ib/II trial using CTCE-9908, the company’s lead anti-cancer product. This trial represents the first investigation of CTCE-9908’s safety and ability to reduce the spread of cancer in humans after several doses. A previously completed Phase I trial demonstrated CTCE-9908 to be safe and well tolerated by study subjects after a single dose. The new trial will involve testing the drug in as many as 30 patients with late-stage c...